D.E. Shaw & Co
LAB icon

D.E. Shaw & Co’s Standard BioTools LAB Stock Holding History

D.E. Shaw & Co’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$183K Buy
+199,084
New +$241K ﹤0.01% 4220
2023
Q4 		– Sell
-144,598
Closed -$419K – 4457
2023
Q3 		$419K Sell
144,598
-199,099
-58% -$521K ﹤0.01% 3490
2023
Q2 		$663K Sell
343,697
-236,806
-41% -$467K ﹤0.01% 3298
2023
Q1 		$1.13M Sell
580,503
-206,711
-26% -$408K ﹤0.01% 3081
2022
Q4 		$921K Sell
787,214
-19,936
-2% -$24.5K ﹤0.01% 3502
2022
Q3 		$888K Sell
807,150
-81,886
-9% -$124K ﹤0.01% 3678
2022
Q2 		$1.42M Buy
889,036
+59,007
+7% +$146K ﹤0.01% 3372
2022
Q1 		$2.98M Sell
830,029
-61,606
-7% -$213K ﹤0.01% 2898
2021
Q4 		$3.5M Buy
891,635
+102,428
+13% +$479K ﹤0.01% 2784
2021
Q3 		$5.2M Buy
789,207
+78,477
+11% +$516K ﹤0.01% 2072
2021
Q2 		$4.38M Buy
710,730
+172,456
+32% +$922K ﹤0.01% 2169
2021
Q1 		$2.43M Sell
538,274
-152,752
-22% -$839K ﹤0.01% 2429
2020
Q4 		$4.15M Buy
691,026
+395,827
+134% +$2.6M ﹤0.01% 2016
2020
Q3 		$2.19M Sell
295,199
-856,072
-74% -$5.91M ﹤0.01% 2337
2020
Q2 		$4.62M Buy
1,151,271
+720,550
+167% +$2.51M 0.01% 1707
2020
Q1 		$1.09M Sell
430,721
-776,464
-64% -$2.55M ﹤0.01% 2663
2019
Q4 		$4.2M Buy
1,207,185
+119,310
+11% +$420K ﹤0.01% 1864
2019
Q3 		$5.04M Buy
1,087,875
+538,869
+98% +$4.24M 0.01% 1640
2019
Q2 		$6.76M Sell
549,006
-384,683
-41% -$4.9M 0.01% 1374
2019
Q1 		$12.4M Buy
933,689
+712,728
+323% +$7.51M 0.02% 971
2018
Q4 		$1.91M Sell
220,961
-22,662
-9% -$177K ﹤0.01% 2195
2018
Q3 		$1.82M Buy
243,623
+50,616
+26% +$360K ﹤0.01% 2259
2018
Q2 		$1.15M Buy
193,007
+55,376
+40% +$316K ﹤0.01% 2620
2018
Q1 		$804K Buy
137,631
+35,941
+35% +$236K ﹤0.01% 2637
2017
Q4 		$599K Sell
101,690
-49,961
-33% -$273K ﹤0.01% 2877
2017
Q3 		$764K Buy
151,651
+69,876
+85% +$294K ﹤0.01% 2663
2017
Q2 		$330K Buy
81,775
+36,142
+79% +$171K ﹤0.01% 2995
2017
Q1 		$260K Buy
+45,633
New +$289K ﹤0.01% 3026
2015
Q3 		– Sell
-19,900
Closed -$482K – 3814
2015
Q2 		$482K Buy
+19,900
New +$628K ﹤0.01% 3178
2014
Q3 		– Sell
-84,872
Closed -$2.5M – 4251
2014
Q2 		$2.5M Sell
84,872
-1,484
-2% -$47.6K ﹤0.01% 2135
2014
Q1 		$3.81M Buy
86,356
+5,596
+7% +$246K 0.01% 1792
2013
Q4 		$3.1M Buy
80,760
+32,673
+68% +$962K ﹤0.01% 2101
2013
Q3 		$1.05M Buy
48,087
+13,522
+39% +$266K ﹤0.01% 2997
2013
Q2 		$604K Buy
+34,565
New +$607K ﹤0.01% 3106

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

D.E. Shaw & Co's LAB Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in Standard BioTools (LAB) in Q1 2026: 199,084 shares worth $183K. The stake represents ﹤0.01% of the portfolio and ranks #4220 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in LAB as recently as Q3 2023.

D.E. Shaw & Co first reported a position in LAB in Q2 2013 and has held it in 34 quarters since. The position peaked at $12.4M in Q1 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • D.E. Shaw & Co held 199,084 shares of Standard BioTools worth $183K as of Q1 2026.
  • Standard BioTools was a new D.E. Shaw & Co position in Q1 2026.
  • Standard BioTools made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4220 holding.
  • D.E. Shaw & Co first reported a position in Standard BioTools in Q2 2013 and has held it in 34 quarters since.
  • D.E. Shaw & Co's Standard BioTools position peaked at $12.4M in Q1 2019.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.